Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sarepta Wins Exon 51 Composition Patent Rights Over BioMarin

Executive Summary

Patent Trial and Appeal Board rules against BioMarin in proceeding to determine who has rights to a composition of matter patent for eteplirsen; last year the board ruled in BioMarin's favor on method of use patent.

Advertisement

Related Content

Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Sarepta's Eteplirsen Approved After Contentious Internal Debate
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register